Beccar Varela, M. & M. Bomchil and Estudio Rosso Alba, Francia & Asociados advise on the acquisition of Biosidus by Acon Investments and Humus Capital
Buenos Aires, June 12, 2018. Beccar Varela advised ACON Bios Investors LP (“ACON”), in partnership with Humus Capital Partners LLC (“HCP”), on the acquisition and investment in Biosidus S.A. (“Biosidus”). In this acquisition, M. & M. Bomchil and Estudio Rosso Alba, Francia & Asociados advised the Sellers. The closing took place on June 5, 2018.
Biosidus is dedicated to the research and development, formulation, manufacture and commercialization of biosimilar pharmaceutical products. ACON and HCP will continue the group’s international expansion strategy, building on its track record of biosimilar pharmaceuticals produced over the last two decades. Biosidus’ product portfolio comprises some of the most successful biosimilars developed to date.
Counsel to ACON Bios Investors LP and Humus Capital Partners LLC: Beccar Varela (partners Tomás Allende and Santiago Montezanti; senior associates Pedro Silvestri, Ana Andrés and Lucía Guardone and associates Juan Francisco Oria and Elizabeth Haag).
Counsel to Sellers: M. & M. Bomchil Abogados (partner Fermín Caride and senior associate Máximo J. Bomchil) and Estudio Rosso Alba, Francia & Asociados (partner Cristian Rosso Alba).
Fusiones & Adquisiciones. “Beccar Varela, M. & M. Bomchil y Estudio Rosso Alba, Francia & Asociados asesoran en la adquisición de Biosidus por parte de ACON Investments y Humus Capital” (gacetilla de prensa, 12.06.2018).